The results indicated that both treatments significantly reduced the number of CD4+CD44+ T cells, most of which were memory T cells, in addition to reducing lung inflammation and lower levels of Th2 cytokines, such as IL-4, IL-5, and IL-13. The gene discussed is CD4; the disease is inflammation.